ClinicalTrials.gg
CompletedNCT05224947GLAM-IIUpdated Apr 1, 2024

Gastric Layering and Monitoring II

An interventional study of Infant Formula in Infant Formula, sponsored by Wageningen University. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-01.

Sponsored by Wageningen University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Rationale: Results from a previous study suggest that gastric layer formation, which is caused by emulsion instability as a result of gastric acidification/digestion, is different between breastmilk and infant formula. The current study focusses on further understanding of these differences by investigating the effect of formula composition.

Objective: To investigate the effect of infant formula composition on intragastric behavior, gastric emptying and postprandial plasma parameters.

Study design: Double-blind cross-over study with two treatments.

Study population: 20 healthy normal-weight males, aged 18-45 y.

Intervention: After an overnight fast, participants will drink sufficient volume of one of the two IFs which differ in composition. Gastric content will be monitored using Magnetic Resonance Imaging (MRI). MRI scans will be done and blood samples will be taken for subsequent analyses at baseline and post prandially .

Main study parameters/endpoints: The primary outcome is gastric behavior. Secondary outcomes are total gastric content volume over time and blood parameters.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The risks associated with participation are low, as both phlebotomy and MRI are eminently safe medical techniques. In addition, the test formula are safe. Each participant will participate in 2 sessions, which require an overnight fast, 9 blood withdrawals (in total 120 mL per visit) and multiple MRI scans over a period of approximately 2 hours. These measurements are non-invasive and carry minimal risk. The burden of the sessions is most likely related to mild discomfort as they have to lie still in the MRI for two hours. This will be minimized by the soft mattress on the bed of the MRI, leg rest and a pillow underneath the head.

02

Conditions studied

  • Infant Formula

Keywords

  • Gastric behaviour
  • Nutrient absorption
03

In context

Lead sponsor

Wageningen University is the lead sponsor of 153 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male
  • Apparently healthy (self-reported)
  • Willing to be informed about incidental findings of pathology
  • Willing to comply with the study procedures

Exclusion criteria

Exclusion Criteria:

  • Allergy or intolerance for cow milk, lactose, soy and/or fish (self-reported)
  • Gastric disorders or regular gastric complaints, for example heart burn

    • Use of medication which alters the normal functioning of the stomach, such as: Medical drug use that influences the GI tract's normal function, e.g. motility, pH etc.: among others use of protein pump inhibitors, antacids, anti-depressants etc. (judged by study doctor)
    • Medical drug use that influences the GI tract's microbiota: antibiotic use within one month prior to the pre-study screening day (judged by study doctor)
  • Smoking (>2 cigarettes a week)
  • Drinking more than 14 glasses of alcohol a week
  • Having given a blood donation in the past two months
  • Hb value below 8.4 mmol/L (as measured with finger-prick method at screening)
  • Having a contra-indication to MRI scanning, including, but not limited to:

    • Pacemakers and defibrillators
    • Intraorbital or intraocular metallic fragments
    • Ferromagnetic implants
    • Claustrophobia
  • Participating in other research during the study period
  • Being an employee or student of the division of human nutrition and health
  • Not having a general practitioner
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Infant formula A

    Other: Infant Formula

  • Experimental
    Infant formula B

    Other: Infant Formula

Interventions

  • OtherInfant Formula

    Two infant formulas differing in composition

06

What researchers measure

Primary outcomes

  1. Gastric layer formation over time (mL) measured with MRI

    Time frame: 2 hours

Secondary outcomes

  1. Total gastric content volume over time (mL)

    Time frame: 2 hours

  2. Concentration of glucose in blood over time

    Time frame: 2 hours

  3. Concentration of insulin in blood over time

    Time frame: 2 hours

  4. Concentration of free fatty acids in blood over time

    Time frame: 2 hours

  5. Concentration of metabolites in blood over time measured with NMR (analysed by Nightingale: 'blood biomarker analysis service' )

    Time frame: 2 hours

Other outcomes

  1. Verbal ratings of hunger, fullness, bloating and nausea.

    Rated on a scale of 0-100, indicating 'not at all' to 'very much' respectively.

    Time frame: 2 hours

07

Study locations

1 site
  • Wageningen University & Research
    Wageningen, Gelderland 6708WE, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05224947
Collaborators
FrieslandCampina
Responsible party
Paul Smeets (Principal Investigator, Wageningen University) — Principal investigator
First posted
Feb 4, 2022
Start date
Jan 28, 2022
Primary completion
Apr 22, 2022
Completion
Apr 22, 2022
Last update
Apr 1, 2024

Study contacts

Paul AM Smeets, PhD
principal investigator · Wageningen University & Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion